• 1
    Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007;448:42734.
  • 2
    Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009;361:206678.
  • 3
    Larsen S, Bendtzen K, Nielsen OH. Extraintestinal manifestations of inflammatory bowel disease: epidemiology, diagnosis, and management. Ann Med 2010;42:97114.
  • 4
    Halme L, Paavola-Sakki P, Turunen U, Lappalainen M, Farkkila M, Kontula K. Family and twin studies in inflammatory bowel disease. World J Gastroenterol 2006;12:366872.
  • 5
    Cooney R, Jewell D. The genetic basis of inflammatory bowel disease. Dig Dis 2009;27:42842.
  • 6
    Thompson AI, Lees CW. Genetics of ulcerative colitis. Inflamm Bowel Dis 2011;17:83148.
  • 7
    Lakatos P-L. Smoking in inflammatory bowel diseases: good, bad or ugly? World J Gastroenterol 2007;13:6134.
  • 8
    Rutgeerts P, Goboes K, Peeters M, Hiele M, Penninckx F, Aerts R et al. Effect of faecal stream diversion on recurrence of Crohn’s disease in the neoterminal ileum. Lancet 1991;338:7714.
  • 9
    Bartel G, Weiss I, Turetschek K, Schima W, Püspök A, Waldhoer T et al. Ingested matter affects intestinal lesions in Crohn’s disease. Inflamm Bowel Dis 2008;14:37482.
  • 10
    Sellon RK, Tonkonogy S, Schultz M, Dieleman LA, Grenther W, Balish E et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 1998;66:522431.
  • 11
    Taurog JD, Richardson JA, Croft JT, Simmons WA, Zhou M, Fernández-Sueiro JL et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 1994;180:235964.
  • 12
    Glocker E-O, Kotlarz D, Boztug K, Gertz EM, Schaffer AA, Noyan F et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med 2009;361:203345.
  • 13
    Kühn R, Löhler J, Rennick D, Rajewsky K, Müller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993;75:26374.
  • 14
    Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989;170:208195.
  • 15
    Commins S, Steinke JW, Borish L. The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29. J Allergy Clin Immunol 2008;121:110811.
  • 16
    Lee MS, Kim Y-J. Signaling pathways downstream of pattern-recognition receptors and their cross talk. Annu Rev Biochem 2007;76:44780.
  • 17
    Günzl P, Bauer K, Hainzl E, Matt U, Dillinger B, Mahr B et al. Anti-inflammatory properties of the PI3K pathway are mediated by IL-10/DUSP regulation. J Leukoc Biol 2010;88:125969.
  • 18
    Bhattacharyya S, Sen P, Wallet M, Long B, Baldwin AS, Tisch R. Immunoregulation of dendritic cells by IL-10 is mediated through suppression of the PI3K/Akt pathway and of I{kappa}B kinase activity. Blood 2004;104:11009.
  • 19
    Koch F, Stanzl U, Jennewein P, Janke K, Heufler C, Kämpgen E et al. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J Exp Med 1996;184:7416.
  • 20
    Corinti S, Albanesi C, la Sala A, Pastore S, Girolomoni G. Regulatory activity of autocrine IL-10 on dendritic cell functions. J Immunol 2001;166:43128.
  • 21
    Zhou L, Tedder T. A distinct pattern of cytokine gene expression by human CD83+ blood dendritic cells. Blood 1995;86:3295301.
  • 22
    Gasche C, Bakos S, Dejaco C, Tillinger W, Zakeri S, Reinisch W. IL-10 secretion and sensitivity in normal human intestine and inflammatory bowel disease. J Clin Immunol 2000;20:36270.
  • 23
    O’Farrell AM, Liu Y, Moore KW, Mui AL. IL-10 inhibits macrophage activation and proliferation by distinct signaling mechanisms: evidence for Stat3-dependent and -independent pathways. EMBO J 1998;17:100618.
  • 24
    McCoy CE, Sheedy FJ, Qualls JE, Doyle SL, Quinn SR, Murray PJ et al. IL-10 inhibits miR-155 induction by Toll-like receptors. J Biol Chem 2010;285:204928.
  • 25
    An H, Xu H, Zhang M, Zhou J, Feng T, Qian C et al. Src homology 2 domain-containing inositol-5-phosphatase 1 (SHIP1) negatively regulates TLR4-mediated LPS response primarily through a phosphatase activity- and PI-3K-independent mechanism. Blood 2005;105:468592.
  • 26
    Park H-J, Lee SJ, Kim S-H, Han J, Bae J, Kim SJ et al. IL-10 inhibits the starvation induced autophagy in macrophages via class I phosphatidylinositol 3-kinase (PI3K) pathway. Mol Immunol 2011;48:7207.
  • 27
    Gutierrez MG, Master SS, Singh SB, Taylor GA, Colombo MI, Deretic V. Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell 2004;119:75366.
  • 28
    Zhang X, Majlessi L, Deriaud E, Leclerc C, Lo-Man R. Coactivation of Syk kinase and MyD88 adaptor protein pathways by bacteria promotes regulatory properties of neutrophils. Immunity 2009;31:76171.
  • 29
    Crepaldi L, Gasperini S, Lapinet JA, Calzetti F, Pinardi C, Liu Y et al. Up-regulation of IL-10R1 expression is required to render human neutrophils fully responsive to IL-10. J Immunol 2001;167:231222.
  • 30
    Bazzoni F, Tamassia N, Rossato M, Cassatella MA. Understanding the molecular mechanisms of the multifaceted IL-10-mediated anti-inflammatory response: lessons from neutrophils. Eur J Immunol 2010;40:23608.
  • 31
    Cai G, Kastelein RA, Hunter CA. IL-10 enhances NK cell proliferation, cytotoxicity and production of IFN-gamma when combined with IL-18. Eur J Immunol 1999;29:265865.
  • 32
    Mocellin S, Panelli M, Wang E, Rossi CR, Pilati P, Nitti D et al. IL-10 stimulatory effects on human NK cells explored by gene profile analysis. Genes Immun 2004;5:62130.
  • 33
    Bailey DP, Kashyap M, Bouton LA, Murray PJ, Ryan JJ. Interleukin-10 induces apoptosis in developing mast cells and macrophages. J Leukoc Biol 2006;80:5819.
  • 34
    Bouton LA, Ramirez CD, Bailey DP, Yeatman CF, Yue J, Wright HV et al. Costimulation with interleukin-4 and interleukin-10 induces mast cell apoptosis and cell-cycle arrest: the role of p53 and the mitochondrion. Exp Hematol 2004;32:113745.
  • 35
    Gillespie SR, DeMartino RR, Zhu J, Chong HJ, Ramirez C, Shelburne CP et al. IL-10 inhibits Fc{epsilon}RI expression in mouse mast cells. J Immunol 2004;172:31818.
  • 36
    Mirmonsef P, Shelburne CP, Fitzhugh Yeatman C, Chong HJ, Ryan JJ. Inhibition of kit expression by IL-4 and IL-10 in murine mast cells: role of STAT6 and phosphatidylinositol 3′-kinase. J Immunol 1999;163:25309.
  • 37
    Chichlowski M, Westwood GS, Abraham SN, Hale LP. Role of mast cells in inflammatory bowel disease and inflammation-associated colorectal neoplasia in IL-10-deficient mice. PLoS ONE 2010;5:e12220.
  • 38
    Werner T, Shkoda A, Haller D. Intestinal epithelial cell proteome in IL-10 deficient mice and IL-10 receptor reconstituted epithelial cells: impact on chronic inflammation. J Proteome Res 2007;6:3691704.
  • 39
    Kaser A, Lee A-H, Franke A, Glickman JN, Zeissig S, Tilg H et al. XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. Cell 2008;134:74356.
  • 40
    Fritz T, Niederreiter L, Adolph T, Blumberg RS, Kaser A. Crohn’s disease: NOD2, autophagy and ER stress converge. Gut 2011;doi: 10.1136/gut.2009.206466.
  • 41
    Saraiva M, Christensen JR, Veldhoen M, Murphy TL, Murphy KM, O’Garra A. Interleukin-10 production by Th1 cells requires interleukin-12-induced STAT4 transcription factor and ERK MAP kinase activation by high antigen dose. Immunity 2009;31:20919.
  • 42
    Ouyang W, Löhning M, Gao Z, Assenmacher M, Ranganath S, Radbruch A et al. Stat6-independent GATA-3 autoactivation directs IL-4-independent Th2 development and commitment. Immunity 2000;12:2737.
  • 43
    Aggarwal S, Ghilardi N, Xie M-H, de Sauvage FJ, Gurney AL. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003;278:19104.
  • 44
    Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGF[beta] in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T Cells. Immunity 2006;24:17989.
  • 45
    Zhou L, Ivanov II, Spolski R, Min R, Shenderov K, Egawa T et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 2007;8:96774.
  • 46
    Xin L, Li Y, Soong L. Role of interleukin-1β in activating the CD11chigh CD45RB− dendritic cell subset and priming leishmania amazonensis- specific CD4+ T cells in vitro and in vivo. Infect Immun 2007;75:501826.
  • 47
    McGeachy MJ, Bak-Jensen KS, Chen Y, Tato CM, Blumenschein W, McClanahan T et al. TGF-[beta] and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain TH-17 cell-mediated pathology. Nat Immunol 2007;8:13907.
  • 48
    Xu J, Yang Y, Qiu G, Lal G, Wu Z, Levy DE et al. c-Maf regulates IL-10 expression during Th17 polarization. J Immunol 2009;182:622636.
  • 49
    Schandené L, Alonso-Vega C, Willems F, Gérard C, Delvaux A, Velu T et al. B7/CD28-dependent IL-5 production by human resting T cells is inhibited by IL-10. J Immunol 1994;152:436874.
  • 50
    Del Prete G, De Carli M, Almerigogna F, Giudizi M, Biagiotti R, Romagnani S. Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol 1993;150:35360.
  • 51
    Roers A, Siewe L, Strittmatter E, Deckert M, Schlüter D, Stenzel W et al. T cell-specific inactivation of the interleukin 10 gene in mice results in enhanced T cell responses but normal innate responses to lipopolysaccharide or skin irritation. J Exp Med 2004;200:128997.
  • 52
    Rubtsov YP, Rasmussen JP, Chi EY, Fontenot J, Castelli L, Ye X et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity 2008;28:54658.
  • 53
    Mills KHG. Regulatory T cells: friend or foe in immunity to infection? Nat Rev Immunol 2004;4:84155.
  • 54
    Waidmann M, Allemand Y, Lehmann J, di Genaro S, Bücheler N, Hamann A et al. Microflora reactive IL-10 producing regulatory T cells are present in the colon of IL-2 deficient mice but lack efficacious inhibition of IFN-γ and TNF-α production. Gut 2002;50:1709.
  • 55
    Maynard CL, Harrington LE, Janowski KM, Oliver JR, Zindl CL, Rudensky AY et al. Regulatory T cells expressing interleukin 10 develop from Foxp3+ and Foxp3− precursor cells in the absence of interleukin 10. Nat Immunol 2007;8:93141.
  • 56
    Round JL, Mazmanian SK. Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc Natl Acad Sci USA 2010;107:122049.
  • 57
    Kitamura K, Farber JM, Kelsall BL. CCR6 marks regulatory T cells as a colon-tropic, IL-10-producing phenotype. J Immunol 2010;185:3295304.
  • 58
    Lim B, Sutherland RM, Zhan Y, Deliyannis G, Brown LE, Lew AM. Targeting CD45RB alters T cell migration and delays viral clearance. Int Immunol 2006;18:291300.
  • 59
    Powrie F, Leach MW, Mauze S, Menon S, Caddle LB, Coffman RL. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity 1994;1:55362.
  • 60
    Murai M, Turovskaya O, Kim G, Madan R, Karp CL, Cheroutre H et al. Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis. Nat Immunol 2009;10:117884.
  • 61
    Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003;4:3306.
  • 62
    Hillhouse EE, Beauchamp C, Chabot-Roy G, Dugas V, Lesage S. Interleukin-10 limits the expansion of immunoregulatory CD4−CD8− T cells in autoimmune-prone non-obese diabetic mice. Immunol Cell Biol 2010;88:77180.
  • 63
    Fischer K, Voelkl S, Heymann J, Przybylski GK, Mondal K, Laumer M et al. Isolation and characterization of human antigen-specific TCR alpha beta+ CD4(−)CD8− double-negative regulatory T cells. Blood 2005;105:282835.
  • 64
    Zhang Z-X, Ma Y, Wang H, Arp J, Jiang J, Huang X et al. Double-negative T cells, activated by xenoantigen, lyse autologous B and T cells using a perforin/granzyme-dependent, Fas-Fas ligand-independent pathway. J Immunol 2006;177:69209.
  • 65
    Strober S, Dejbachsh-Jones S, Van Vlasselaer P, Duwe G, Salimi S, Allison J. Cloned natural suppressor cell lines express the CD3+CD4−CD8− surface phenotype and the alpha, beta heterodimer of the T cell antigen receptor. J Immunol 1989;143:111822.
  • 66
    Chen W, Ford MS, Young KJ, Zhang L. Infusion of in vitro-generated DN T regulatory cells induces permanent cardiac allograft survival in mice. Transplant Proc 2003;35:247980.
  • 67
    Young KJ, DuTemple B, Phillips MJ, Zhang L. Inhibition of graft-versus-host disease by double-negative regulatory T cells. J Immunol 2003;171:13441.
  • 68
    Wang R, Wang-Zhu Y, Grey H. Interactions between double positive thymocytes and high affinity ligands presented by cortical epithelial cells generate double negative thymocytes with T cell regulatory activity. Proc Natl Acad Sci USA 2002;99:21816.
  • 69
    Rousset F, Garcia E, Defrance T, Péronne C, Vezzio N, Hsu DH et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA 1992;89:18903.
  • 70
    Itoh K, Hirohata S. The role of IL-10 in human B cell activation, proliferation, and differentiation. J Immunol 1995;154:434150.
  • 71
    Brière F, Servet-Delprat C, Bridon JM, Saint-Remy JM, Banchereau J. Human interleukin 10 induces naive surface immunoglobulin D+ (sIgD+) B cells to secrete IgG1 and IgG3. J Exp Med 1994;179:75762.
  • 72
    Fillatreau S, Gray D, Anderton SM. Not always the bad guys: B cells as regulators of autoimmune pathology. Nat Rev Immunol 2008;8:3917.
  • 73
    Mizoguchi A, Mizoguchi E, Takedatsu H, Blumberg RS, Bhan AK. Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity 2002;16:21930.
  • 74
    Davidson NJ, Leach MW, Fort MM, Thompson-Snipes L, Kühn R, Müller W et al. T helper cell 1-type CD4+ T cells, but not B cells, mediate colitis in interleukin 10-deficient mice. J Exp Med 1996;184:24151.
  • 75
    Kontoyiannis D, Kotlyarov A, Carballo E, Alexopoulou L, Blackshear PJ, Gaestel M et al. Interleukin-10 targets p38 MAPK to modulate ARE-dependent TNF mRNA translation and limit intestinal pathology. EMBO J 2001;20:376070.
  • 76
    Crawley JB, Williams LM, Mander T, Brennan FM, Foxwell BMJ. Interleukin-10 stimulation of phosphatidylinositol 3-kinase and p70 S6 kinase is required for the proliferative but not the antiinflammatory effects of the cytokine. J Biol Chem 1996;271:1635762.
  • 77
    Ricchetti GA, Williams LM, Foxwell BMJ. Heme oxygenase 1 expression induced by IL-10 requires STAT-3 and phosphoinositol-3 kinase and is inhibited by lipopolysaccharide. J Leukoc Biol 2004;76:71926.
  • 78
    Grundtner P, Gruber S, Murray SS, Vermeire S, Rutgeerts P, Decker T et al. The IL-10R1 S138G loss-of-function allele and ulcerative colitis. Genes Immun 2009;10:8492.
  • 79
    Gasche C, Grundtner P, Zwirn P, Reinisch W, Shaw SH, Zdanov A et al. Novel variants of the IL-10 receptor 1 affect inhibition of monocyte TNF-alpha production. J Immunol 2003;170:557882.
  • 80
    Gruber SG, Gloria Luciani M, Grundtner P, Zdanov A, Gasche C. Differential signaling of cmvIL-10 through common variants of the IL-10 receptor 1. Eur J Immunol 2008;38:336575.
  • 81
    Finsterbusch M, Khare V, Campregher C, Evstatiev R, Gasche C. An intracytoplasmic IL-10 receptor variant permits rapid reduction in STAT3 activation. Genes Immun (in press).
  • 82
    Hofer H, Neufeld JB, Oesterreicher C, Grundtner P, Wrba F, Gangl A et al. Bi-allelic presence of the interleukin-10 receptor 1 G330R allele is associated with cirrhosis in chronic HCV-1 infection. Genes Immun 2005;6:2427.
  • 83
    Gasche C, Reinisch W, Huber W-D, Leshinsky-Silver E, Levine A, Abdul-Baki H et al. IL-10RA truncation mutations and semite populations. Inflamm Bowel Dis 2010;doi: 10.1002/ibd.21495.
  • 84
    Ho AS, Wei SH, Mui AL, Miyajima A, Moore KW. Functional regions of the mouse interleukin-10 receptor cytoplasmic domain. Mol Cell Biol 1995;15:504353.
  • 85
    Franke A, Balschun T, Karlsen TH, Sventoraityte J, Nikolaus S, Mayr G et al. Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet 2008;40:131923.
  • 86
    Anderson CA et al. Investigation of Crohn’s disease risk loci in ulcerative colitis further defines their molecular relationship. Gastroenterology 2009;136:5239.e3.
  • 87
    Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat Genet 2008;40:95562.
  • 88
    Spencer SD, Di Marco F, Hooley J, Pitts-Meek S, Bauer M, Ryan AM et al. The orphan receptor CRF2-4 is an essential subunit of the interleukin 10 receptor. J Exp Med 1998;187:5718.
  • 89
    Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. Recognition of commensal microflora by Toll-like receptors is required for intestinal homeostasis. Cell 2004;118:22941.
  • 90
    Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature 2001;411:6036.
  • 91
    Hugot J-P, Chamaillard M, Zouali H, Lesage S, Cezard J-P, Belaiche J et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature 2001;411:599603.
  • 92
    Hedl M, Abraham C. Secretory mediators regulate Nod2-induced tolerance in human macrophages. Gastroenterology 2011;140:23141.
  • 93
    Travassos LH, Carneiro LAM, Ramjeet M, Hussey S, Kim Y-G, Magalhaes JG et al. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat Immunol 2010;11:5562.
  • 94
    Wehkamp J, Salzman NH, Porter E, Nuding S, Weichenthal M, Petras RE et al. Reduced Paneth cell alpha-defensins in ileal Crohn’s disease. Proc Natl Acad Sci USA 2005;102:1812934.
  • 95
    Kobayashi KS, Chamaillard M, Ogura Y, Henegariu O, Inohara N, Nuñez G et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 2005;307:7314.
  • 96
    Maeda S, Hsu L-C, Liu H, Bankston LA, Iimura M, Kagnoff MF et al. Nod2 mutation in Crohn’s disease potentiates NF-κB activity and IL-1ß processing. Science 2005;307:7348.
  • 97
    Noguchi E, Homma Y, Kang X, Netea MG, Ma X. A Crohn’s disease-associated NOD2 mutation suppresses transcription of human IL10 by inhibiting activity of the nuclear ribonucleoprotein hnRNP-A1. Nat Immunol 2009;10:4719.
  • 98
    Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010;11:37384.
  • 99
    Karrasch T, Kim J-S, Muhlbauer M, Magness ST, Jobin C. Gnotobiotic IL-10−/−;NF-κBEGFP mice reveal the critical role of TLR/NF-κb signaling in commensal bacteria-induced colitis. J Immunol 2007;178:652232.
  • 100
    Uronis JM, Mühlbauer M, Herfarth HH, Rubinas TC, Jones GS, Jobin C et al. Modulation of the intestinal microbiota alters colitis-associated colorectal cancer susceptibility. PLoS ONE 2009;4:e6026.
  • 101
    Chang J, Kunkel SL, Chang C-H. Negative regulation of MyD88-dependent signaling by IL-10 in dendritic cells. Proc Natl Acad Sci USA 2009;106:1832732.
  • 102
    Saraiva M, O’Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol 2010;10:17081.
  • 103
    Netea MG, Van der Meer JWM, Sutmuller RP, Adema GJ, Kullberg B-J. From the Th1/Th2 paradigm towards a Toll-like receptor/T-helper bias. Antimicrob Agents Chemother 2005;49:39916.
  • 104
    Sandborn W, Feagan B, Fedorak R, Scherl E, Fleisher M, Katz S et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease. Gastroenterology 2008;135:113041.
  • 105
    Davidson NJ, Hudak SA, Lesley RE, Menon S, Leach MW, Rennick DM et al. IL-12, but not IFN-gamma, plays a major role in sustaining the chronic phase of colitis in IL-10-deficient mice. J Immunol 1998;161:31439.
  • 106
    Yen D, Cheung J, Scheerens H, Poulet F, McClanahan T, Mckenzie B et al. IL-23 is essential for T cell–mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 2006;116:13106.
  • 107
    Zhou L, Nazarian AA, Smale ST. Interleukin-10 inhibits interleukin-12 p40 gene transcription by targeting a late event in the activation pathway. Mol Cell Biol 2004;24:238596.
  • 108
    Goettel JA, Scott Algood HM, Olivares-Villagómez D, Washington MK, Chaturvedi R, Wilson KT et al. KSR1 protects from interleukin-10 deficiency-induced colitis in mice by suppressing T-lymphocyte interferon-γ production. Gastroenterology 2011;140:26574.
  • 109
    Wilson MS, Ramalingam TR, Rivollier A, Shenderov K, Mentink-Kane MM, Madala SK et al. Colitis and intestinal inflammation in IL10−/− mice results from IL-13R[alpha]2-mediated attenuation of IL-13 activity. Gastroenterology 2011;140:25464.
  • 110
    Horwitz BH. The straw that stirs the drink: insight into the pathogenesis of inflammatory bowel disease revealed through the study of microflora-induced inflammation in genetically modified mice. Inflamm Bowel Dis 2007;13:490500.
  • 111
    Kandiel A, Lashner B. Cytomegalovirus colitis complicating inflammatory bowel disease. Am J Gastroenterol 2006;101:285765.
    Direct Link:
  • 112
    Polić B, Hengel H, Krmpotić A, Trgovcich J, Pavić I, Lučin P et al. Hierarchical and redundant lymphocyte subset control precludes cytomegalovirus replication during latent infection. J Exp Med 1998;188:104754.
  • 113
    Karrer U, Sierro S, Wagner M, Oxenius A, Hengel H, Koszinowski UH et al. Memory inflation: continuous accumulation of antiviral CD8+ T cells over time. J Immunol 2003;170:20229.
  • 114
    Jones M, Ladell K, Wynn KK, Stacey MA, Quigley MF, Gostick E et al. IL-10 restricts memory T cell inflation during cytomegalovirus infection. J Immunol 2010;185:358392.
  • 115
    Kotenko SV, Saccani S, Izotova LS, Mirochnitchenko OV, Pestka S. Human cytomegalovirus harbors its own unique IL-10 homolog (cmvIL-10). Proc Natl Acad Sci USA 2000;97:1695700.
  • 116
    Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001;19:683765.
  • 117
    Yoon SI, Jones BC, Logsdon NJ, Walter MR. Same structure, different function: crystal structure of the Epstein–Barr virus IL-10 bound to the soluble IL-10R1 chain. Structure 2005;13:55164.
  • 118
    Raftery MJ, Wieland D, Gronewald S, Kraus AA, Giese T, Schönrich G. Shaping phenotype, function, and survival of dendritic cells by cytomegalovirus-encoded IL-10. J Immunol 2004;173:338391.
  • 119
    Lin Y-L, Chang P-C, Wang Y, Li M. Identification of novel viral interleukin-10 isoforms of human cytomegalovirus AD169. Virus Res 2008;131:21323.
  • 120
    Xu C, Bailly-Maitre B, Reed JC. Endoplasmic reticulum stress: cell life and death decisions. J Clin Invest 2005;115:265664.
  • 121
    Kaser A, Blumberg RS. Endoplasmic reticulum stress and intestinal inflammation. Mucosal Immunol 2010;3:116.
  • 122
    Baumeister P, Luo S, Skarnes WC, Sui G, Seto E, Shi Y et al. Endoplasmic reticulum stress induction of the Grp78/BiP promoter: activating mechanisms mediated by YY1 and its interactive chromatin modifiers. Mol Cell Biol 2005;25:452940.
  • 123
    Heath-Engel HM, Chang NC, Shore GC. The endoplasmic reticulum in apoptosis and autophagy: role of the BCL-2 protein family. Oncogene 2008;27:641933.
  • 124
    Shkoda A, Ruiz PA, Daniel H, Kim SC, Rogler G, Sartor RB et al. Interleukin-10 blocked endoplasmic reticulum stress in intestinal epithelial cells: impact on chronic inflammation. Gastroenterology 2007;132:190207.
  • 125
    Pahl HL, Baeuerle PA. A novel signal transduction pathway from the endoplasmic reticulum to the nucleus is mediated by transcription factor NF-kappa B. EMBO J 1995;14:25808.
  • 126
    Schottelius AJ, Mayo MW, Sartor RB, Baldwin AS. Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding. J Biol Chem 1999;274:3186874.
  • 127
    Drechsler Y, Dolganiuc A, Norkina O, Romics L, Li W, Kodys K et al. Heme oxygenase-1 mediates the anti-inflammatory effects of acute alcohol on IL-10 induction involving p38 MAPK activation in monocytes. J Immunol 2006;177:2592600.
  • 128
    Franco A, Almanza G, Burns JC, Wheeler M, Zanetti M. Endoplasmic reticulum stress drives a regulatory phenotype in human T-cell clones. Cell Immunol 2010;266:16.
  • 129
    Weiss E, Mamelak AJ, La Morgia S, Wang B, Feliciani C, Tulli A et al. The role of interleukin 10 in the pathogenesis and potential treatment of skin diseases. J Am Acad Dermatol 2004;50:65775.
  • 130
    Peranteau WH, Zhang L, Muvarak N, Badillo AT, Radu A, Zoltick PW et al. IL-10 overexpression decreases inflammatory mediators and promotes regenerative healing in an adult model of scar formation. J Invest Dermatol 2008;128:185260.
  • 131
    Bober LA, Rojas-Triana A, Jackson JV, Leach MW, Manfra D, Narula SK et al. Regulatory effects of interleukin-4 and interleukin-10 on human neutrophil function ex vivo and on neutrophil influx in a rat model of arthritis. Arthritis Rheum 2000;43:26607.
  • 132
    Oberholzer A, Oberholzer C, Moldawer LL. Interleukin-10: a complex role in the pathogenesis of sepsis syndromes and its potential as an anti-inflammatory drug. Crit Care Med 2002;30:S5863.
  • 133
    Pajkrt D, Camoglio L, Tiel-van Buul MC, de Bruin K, Cutler DL, Affrime MB et al. Attenuation of proinflammatory response by recombinant human IL-10 in human endotoxemia: effect of timing of recombinant human IL-10 administration. J Immunol 1997;158:39717.
  • 134
    Wissing KM, Morelon E, Legendre C, De Pauw L, LeBeaut A, Grint P et al. A pilot trial of recombinant human interleukin-10 in kidney transplant recipients receiving OKT3 induction therapy. Transplantation 1997;64:9991006.
  • 135
    Shinozaki K, Yahata H, Hayamizu K, Tashiro H, Fan X, Okimoto T et al. Adenovirus-mediated allograft transduction of interleukin-10: role in the induction phase of liver allograft acceptance. Transpl Proc 2000;32:2478.
  • 136
    Engles RE, Huber TS, Zander DS, Hess PJ, Welborn MB, Moldawer LL et al. Exogenous human recombinant interleukin-10 attenuates hindlimb ischemia-reperfusion injury. J Surg Res 1997;69:4258.
  • 137
    Mallat Z, Besnard S, Duriez M, Deleuze V, Emmanuel F, Bureau MF et al. Protective role of interleukin-10 in atherosclerosis. Circ Res 1999;85:e1724.
  • 138
    Eksioglu EA, Bess J, Jones G, Dettloff J, Dangmeon P, Dong H-J et al. Characterization of anti-HCV antibodies in IL-10-treated patients. Viral Immunol 2010;23:35968.
  • 139
    Nelson DR, Lauwers GY, Lau JY, Davis GL. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology 2000;118:65560.
  • 140
    Angel JB, Jacobson MA, Skolnik PR, Giordano M, Shapiro L, LeBeaut A et al. A multicenter, randomized, double-blind, placebo-controlled trial of recombinant human interleukin-10 in HIV-infected subjects. AIDS 2000;14:25038.
  • 141
    Sherman S, Cheng C-L, Costamagna G, Binmoeller KF, Puespoek A, Aithal GP et al. Efficacy of recombinant human interleukin-10 in prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis in subjects with increased risk. Pancreas 2009;38:26774.
  • 142
    Mulder CJ, Wahab PJ, Meijer JW, Metselaar E. A pilot study of recombinant human interleukin-10 in adults with refractory coeliac disease. Eur J Gastroenterol Hepatol 2001;13:11838.
  • 143
    Braat H, Rottiers P, Hommes DW, Huyghebaert N, Remaut E, Remon J-P et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn’s disease. Clin Gastroenterol Hepatol 2006;4:7549.
  • 144
    van Deventer SJ, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn’s disease. Crohn’s Disease Study Group. Gastroenterology 1997;113:3839.
  • 145
    Colombel JF, Rutgeerts P, Malchow H, Jacyna M, Nielsen OH, Rask-Madsen J et al. Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn’s disease. Gut 2001;49:426.
  • 146
    Schreiber S, Fedorak RN, Nielsen OH, Wild G, Williams CN, Nikolaus S et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn’s disease. Crohn’s Disease IL-10 Cooperative Study Group. Gastroenterology 2000;119:146172.
  • 147
    Tilg H, van Montfrans C, van den Ende A, Kaser A, van Deventer SJH, Schreiber S et al. Treatment of Crohn’s disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon γ. Gut 2002;50:1915.
  • 148
    Tilg H, Ulmer H, Kaser A, Weiss G. Role of IL-10 for induction of anemia during inflammation. J Immunol 2002;169:22049.
  • 149
    Dejaco C, Reinisch W, Lichtenberger C, Waldhoer T, Kuhn I, Tilg H et al. In vivo effects of recombinant human interleukin-10 on lymphocyte phenotypes and leukocyte activation markers in inflammatory bowel disease. J Investig Med 2000;48:44956.
  • 150
    Tillinger W, Jilch R, Jilma B, Brunner H, Koeller U, Lichtenberger C et al. Expression of the high-affinity IgG receptor FcRI (CD64) in patients with inflammatory bowel disease: a new biomarker for gastroenterologic diagnostics. Am J Gastroenterol 2009;104:1029.
  • 151
    Bhavsar MD, Amiji MM. Oral IL-10 gene delivery in a microsphere-based formulation for local transfection and therapeutic efficacy in inflammatory bowel disease. Gene Ther 2008;15:12009.
  • 152
    Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000;289:13525.
  • 153
    Waeytens A, Ferdinande L, Neirynck S, Rottiers P, De Vos M, Steidler L et al. Paracellular entry of interleukin-10 producing Lactococcus lactis in inflamed intestinal mucosa in mice. Inflamm Bowel Dis 2008;14:4719.
  • 154
    Lindsay JO, Sandison A, Cohen P, Brennan FM, Hodgson HJF. IL-10 gene therapy is therapeutic for dextran sodium sulfate-induced murine colitis. Dig Dis Sci 2004;49:132734.
  • 155
    Lindsay JO, Ciesielski CJ, Scheinin T, Brennan FM, Hodgson HJ. Local delivery of adenoviral vectors encoding murine interleukin 10 induces colonic interleukin 10 production and is therapeutic for murine colitis. Gut 2003;52:9817.
  • 156
    Foligne B, Dessein R, Marceau M, Poiret S, Chamaillard M, Pot B et al. Prevention and treatment of colitis with Lactococcus lactis secreting the immunomodulatory Yersinia LcrV protein. Gastroenterology 2007;133:86274.